

Resource Summary Report

Generated by PRECISE-TBI on Aug 1, 2026

B6.129-Idua^{tm1Clk/J}

RRID:IMSR_JAX:004068

Type: Organism

Proper Citation

RRID:IMSR_JAX:004068

Organism Information

URL: <https://www.jax.org/strain/004068>

Proper Citation: RRID:IMSR_JAX:004068

Description: Mus musculus with name B6.129-Idua^{tm1Clk/J} from IMSR.

Species: Mus musculus

Notes: gene symbol note: iduronidase; alpha-L; mutant strain|congenic strain: Idua

Affected Gene: iduronidase; alpha-L

Genomic Alteration: targeted mutation 1; Lorne A Clarke

Catalog Number: JAX:004068

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: sperm

Organism Name: B6.129-Idua^{tm1Clk/J}

Record Creation Time: 20250513T053642+0000

Record Last Update: 20260801T050345+0000

Ratings and Alerts

No rating or validation information has been found for B6.129-Idua^{tm1Clk/J}.

No alerts have been found for B6.129-Idua^{tm1Clk/J}.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Gaffke L, et al. (2023) Actin Cytoskeleton Polymerization and Focal Adhesion as Important Factors in the Pathomechanism and Potential Targets of Mucopolysaccharidosis Treatment. *Cells*, 12(13).

Żabińska M, et al. (2023) Decreased Levels of Chaperones in Mucopolysaccharidoses and Their Elevation as a Putative Auxiliary Therapeutic Approach. *Pharmaceutics*, 15(2).

Wąsierska M, et al. (2022) Murine Fibroblasts and Primary Hepatocytes as Tools When Studying the Efficacy of Potential Therapies for Mucopolysaccharidosis Type I. *International journal of molecular sciences*, 24(1).

Lin Y, et al. (2020) miR-143 Regulates Lysosomal Enzyme Transport across the Blood-Brain Barrier and Transforms CNS Treatment for Mucopolysaccharidosis Type I. *Molecular therapy : the journal of the American Society of Gene Therapy*, 28(10), 2161.

Ghosh A, et al. (2019) Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I. *Molecular therapy. Methods & clinical development*, 13, 321.

Le SQ, et al. (2018) A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I. *Molecular therapy. Methods & clinical development*, 8, 42.

Khalid O, et al. (2016) Immune-Mediated Inflammation May Contribute to the Pathogenesis of Cardiovascular Disease in Mucopolysaccharidosis Type I. *PloS one*, 11(3), e0150850.

Watson HA, et al. (2014) Heparan sulfate inhibits hematopoietic stem and progenitor cell migration and engraftment in mucopolysaccharidosis I. *The Journal of biological chemistry*, 289(52), 36194.